HLA-C and neoplasm: The main challenge is to identify, among the in silico predicted neoantigens, those able to trigger a robust immune response in the patient, as this could potentially result in the eradication of tumor cells presenting the neoantigens.14, 15, 16 Among the in silico identified neoantigen candidates, only a small number renders peptides (neoepitopes) that can be presented on MHC molecules on the cell surface, and only few of these pMHC complexes might be immunogenic, therefore eliciting a T cell response.